A vitamin D drug, e.g. calcitriol, is used to manufacture a medicament for the treatment of a hyperproliferative skin disease in a human, wherein the disease responds to treatment with the drug, the human is susceptible to hypercalcemia when the drug is administered at antiproliferative doses, and the medicament is for administration to the human of therapeutically effective pulse doses of the drug not more often than once every three days in an amount to treat the hyperproliferative skin disease, without inducing severe symptomatic hypercalcemia.
